We are live on ! Find out more
TMBR

Timber Pharmaceuticals, Inc.

Delisted

TMBR was delisted on the 28th of November, 2023.

14 hedge funds and large institutions have $540K invested in Timber Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

18% less funds holding

Funds holding: 1714 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

80% less capital invested

Capital invested by funds: $2.63M → $540K (-$2.1M)

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.3%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
3
Closed
7
Calls
Puts
Net Calls
Net Calls Change

TMBR Hedge Fund Activity: Q2 2019 in Review

14 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2019, worth a combined $540K — down 80% from $2.63M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TMBR and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Virtu Financial, adding an estimated $177K. The largest seller was Vivo Capital, cutting an estimated $426K.

  • 14 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2019, down from 17 in Q1 2019.
  • Funds reported $540K of Timber Pharmaceuticals, Inc. stock for Q2 2019, down 80% quarter-over-quarter.
  • 4 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2019 and 7 closed out, a net change of -3 holders.
  • The largest Timber Pharmaceuticals, Inc. buyer in Q2 2019 was Virtu Financial, an estimated $177K added.
  • The largest Timber Pharmaceuticals, Inc. seller in Q2 2019 was Vivo Capital, an estimated $426K sold.

Based on aggregated 13F filings for Q2 2019.